rescinnamine
Trade name: moderil
Small moleculeapproved
Approved
Oct 31, 1956
Rescinnamine is an alkaloid isolated from Rauvolfia serpentina and approved by FDA for the treatment of hypertension. The mechanism of rescinnamine is not established, but probably resembles that of reserpine. Rescinnamine approval was discontinued by unknown reason. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- Synaptic vesicular amine transporterINHIBITOR
SLC18A2 inhibitor
Approval history
- approvedOct 31, 1956
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)\C=C\C6=CC(OC)=C(OC)C(OC)=C6- Mol. weight
- 634.716 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaRescinnamine ↗
- NCATSQ6W1F7DJ2D ↗
- ChEMBLCHEMBL1668 ↗
Also known as
- 3,4,5-trimethoxycinnamoyl methyl reserpate
- 3,4,5-trimethoxycinnamoyl methyl reserpate
- cinnaloid
- cinnasil
- cinnasil
- methyl trimethoxycinnamoylreserpate
- moderil
- moderil
- moderil
- moderil
- moderil
- rescinnamin
- rescinnamine
- rescinnamine
- rescinnamine
- rescinnamine
- rescinnamine
- rescinnamine
- rescinnamine
- rescinnamine
- rescinnamine
- rescinnamine
- rescisan
- resealoid
- reserpinine
- scinnamina
- trimethoxy cinnamoyl reserpate de methyl
- trimethoxy cinnamoyl reserpate de methyl
- tsuruselpi s
- tsuruselpi s
- yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)-
Organizations
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Panray Corp. | For profit | MKTG | — |
| Pfizer | For profit | SYN | Oct 31, 1956 |
| Pfizer | For profit | NDA | Oct 31, 1956 |